- Home
- OSBC vs URGN Comparison
OSBC vs URGN Comparison
Compare OSBC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSBC
- URGN
- Stock Information
- Founded
- OSBC 1981
- URGN 2004
- Country
- OSBC United States
- URGN United States
- Employees
- OSBC N/A
- URGN N/A
- Industry
- OSBC Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- OSBC Finance
- URGN Health Care
- Exchange
- OSBC Nasdaq
- URGN Nasdaq
- Market Cap
- OSBC 952.7M
- URGN 1.1B
- IPO Year
- OSBC N/A
- URGN 2017
- Fundamental
- Price
- OSBC $18.05
- URGN $25.43
- Analyst Decision
- OSBC Buy
- URGN Strong Buy
- Analyst Count
- OSBC 4
- URGN 8
- Target Price
- OSBC $21.63
- URGN $28.50
- AVG Volume (30 Days)
- OSBC 382.5K
- URGN 1.3M
- Earning Date
- OSBC 10-22-2025
- URGN 11-06-2025
- Dividend Yield
- OSBC 1.55%
- URGN N/A
- EPS Growth
- OSBC N/A
- URGN N/A
- EPS
- OSBC 1.48
- URGN N/A
- Revenue
- OSBC $288,832,000.00
- URGN $96,516,000.00
- Revenue This Year
- OSBC $27.16
- URGN $35.07
- Revenue Next Year
- OSBC $12.26
- URGN $117.83
- P/E Ratio
- OSBC $12.22
- URGN N/A
- Revenue Growth
- OSBC 9.38
- URGN 8.00
- 52 Week Low
- OSBC $14.14
- URGN $3.42
- 52 Week High
- OSBC $19.46
- URGN $25.60
- Technical
- Relative Strength Index (RSI)
- OSBC 51.00
- URGN 70.50
- Support Level
- OSBC $17.61
- URGN $22.70
- Resistance Level
- OSBC $18.71
- URGN $24.89
- Average True Range (ATR)
- OSBC 0.41
- URGN 1.87
- MACD
- OSBC -0.06
- URGN 0.24
- Stochastic Oscillator
- OSBC 46.88
- URGN 99.19
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.